Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study - Gadgeel, S M; Gandhi, L; Riely, G J (Lancet Oncol, 2014)
, et al.